BRIEF—Hansa writes up value of Idefirix after EU nod

Sweden’s Hansa Biopharma has written up certain intangible assets, following a conditional approval in the EU and UK for Idefirix (imlifidase).

The product, which is used for desensitization treatment of highly sensitized adult kidney transplant patients, is now estimated by Hansa to have a value of around $130 million.

Hansa said the value of the asset has been independently determined by applying the so-called “income approach,” and that the write-up would not impact its financial statements, following International Financial Reporting Standards (IFRS).

Hansa is a rare disease specialist, focusing on innovative, lifesaving and life altering treatments for people with rare immunological conditions.